Key Drivers
- Liquidity cushion
- Cash burn
- Negative equity
AIAI Summary
NBTX has shifted from a speculative biotech to a late-stage, catalyst-driven story with a longer cash runway, but the sharp rally already prices in much of the good news, so the key trade is whether NANORAY-312 and the 2026 readouts deliver enough clinical proof to justify the rerating before momentum outruns fundamentals.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity cushion
- •Cash burn
- •Negative equity
NBTX has enough near-term liquidity to keep operating, but persistent losses, heavy cash burn, negative equity, and elevated leverage make the stock fundamentally fragile and likely overpriced.
Price Behavior
Key Price Behavior Insights:
- •Breakout trend
- •Pullback risk
- •Key support hold
NBTX has broken out of its April base into a strong uptrend over the last month, but the pullback from $55.07 suggests the move is stretched and may need to hold $48.24–$45.49 to stay intact.
Sharp rally from the low-$30s to the low-$50s, followed by a pullback from $55.07 that hints at profit-taking
Sentiment & News
Key News Insights:
- •Preclinical Validation
- •Phase 3 Progress
- •Analyst Support
Nanobiotix delivered a favorable run of updates with promising preclinical Nanoprimer data, FDA acceptance of a Phase 3 protocol amendment, and continued Moderate Buy analyst support.
This is modestly bullish for NBTX, as it strengthens confidence in both pipeline execution and regulatory momentum
Similar Companies in Healthcare
Other companies in the same sector with AI ratings